frontiers | Frontiers in Public Health

TYPE Correction
PUBLISHED 13 November 2024
DOI 10.3389/fpubh.2024.1517339

OPEN ACCESS

EDITED AND REVIEWED BY
Charlotte Cosemans,
University of Hasselt, Belgium

*CORRESPONDENCE
Kaytlin Krutsch
✉ Kaytlin.Krutsch@ttuhsc.edu

†These authors have contributed equally to this work

RECEIVED 25 October 2024
ACCEPTED 31 October 2024
PUBLISHED 13 November 2024

CITATION
Falconi S, Okimi A, Wesley S, Sethi P, Datta P and Krutsch K (2024) Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible. *Front. Public Health* 12:1517339. doi: 10.3389/fpubh.2024.1517339

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

Sirin Falconi[1†], Abiodun Okimi[1†], Shaun Wesley[2†], Pooja Sethi[3†], Palika Datta[4†] and Kaytlin Krutsch[4*†]

[1]School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States, [2]Department of Obstetrics and Gynecology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, United States, [3]Department of Cardiology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States, [4]Department of Obstetrics and Gynecology, School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States

KEYWORDS

heart failure, entresto, lactation, pharmacology, peripartum cardiomyopathy (PPCM), maternal health

A Corrigendum on
The concentration of maternal sacubitril/valsartan transferred into human milk is negligible

by Falconi, S., Okimi, A., Wesley, S., Sethi, P., Datta, P., and Krutsch, K. (2024). *Front. Public Health*. 12:1389513. doi: 10.3389/fpubh.2024.1389513

In the published article, there was an error. The currently published article does not acknowledge a previously published study. We would like to add the missing data and properly reference the earlier work.

A correction has been made to **Discussion**, paragraph one.

This sentence previously stated:

"There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) or ARB (e.g., valsartan) into human milk, limiting the use of these drug classes in breastfeeding mothers suffering from HF."

The corrected sentence appears below:

"There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) into human milk. A single case series has reported the limited transfer of one ARB, candesartan, into human milk (25). This scarcity of data restricts the use of these drug classes in breastfeeding mothers suffering from HF."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

25. Coberger ED, Jensen BP, Dalrymple JM. Transfer of candesartan into human breast milk. *Obstet Gynecol.* (2019) 134:481–4. doi: 10.1097/AOG.0000000000003446